rivastigmine has been researched along with Psychotic Disorders in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beireis, LA; Burgett, RN; Farley, TM | 1 |
| Chang, HA; Hsu, CC; Kao, YC; Ku, SC; Tzeng, NS | 1 |
| Osborn, GG; Saunders, AV | 1 |
| Jayaram, MB; Kour, K; Singh, J | 1 |
| Ballmaier, M; Casamenti, F; Mazzoncini, R; Pepeu, G; Scali, C; Spano, PF; Zoli, M | 1 |
| Antonello, RM; Bava, A; Cazzato, G; Griggio, S; Moretti, R; Torre, P; Ukmar, M | 1 |
| Diraoui, S; Jansen, PA; van Melick, EJ | 1 |
| Luce, AK; McKeith, IG; Reading, PJ | 1 |
2 review(s) available for rivastigmine and Psychotic Disorders
| Article | Year |
|---|---|
Current treatments for patients with Alzheimer disease.
Topics: Aggression; Alzheimer Disease; Behavior Therapy; Cholinesterase Inhibitors; Depression; Excitatory Amino Acid Antagonists; Galantamine; Health Status; Humans; Memantine; Neuroprotective Agents; Parasympathomimetics; Phenylcarbamates; Psychomotor Agitation; Psychotherapy; Psychotic Disorders; Rivastigmine; Time Factors; United States; United States Food and Drug Administration | 2010 |
Acetylcholinesterase inhibitors for schizophrenia.
Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Psychotic Disorders; Randomized Controlled Trials as Topic; Rivastigmine; Schizophrenia; Schizophrenic Psychology | 2012 |
2 trial(s) available for rivastigmine and Psychotic Disorders
| Article | Year |
|---|---|
Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study.
Topics: Aged; Aged, 80 and over; Aspirin; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Dementia, Vascular; Drug Therapy, Combination; Female; Humans; Male; Nimodipine; Phenylcarbamates; Psychotic Disorders; Rivastigmine; Treatment Outcome; Vasodilator Agents | 2004 |
Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.
Topics: Aged; Carbamates; Caregivers; Cognition Disorders; Female; Follow-Up Studies; Hallucinations; Humans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Psychotic Disorders; Rivastigmine; Stress, Psychological; Treatment Outcome | 2001 |
4 other study(ies) available for rivastigmine and Psychotic Disorders
| Article | Year |
|---|---|
Acute treatment of psychotic symptoms in a newly diagnosed Lewy body dementia patient with an accelerated titration schedule of rivastigmine and de-escalation of antipsychotics.
Topics: Aged; Antipsychotic Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Hallucinations; Humans; Lewy Body Disease; Male; Psychotic Disorders; Quetiapine Fumarate; Rivastigmine | 2019 |
Psychotic episode in a patient with Alzheimer's dementia while shifting from the oral to patch form of rivastigmine.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Dementia; Humans; Male; Phenylcarbamates; Psychotic Disorders; Rivastigmine | 2014 |
Rivastigmine antagonizes deficits in prepulse inhibition induced by selective immunolesioning of cholinergic neurons in nucleus basalis magnocellularis.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Antibodies, Monoclonal; Basal Nucleus of Meynert; Carbamates; Cerebral Cortex; Choline O-Acetyltransferase; Cholinergic Fibers; Cholinesterase Inhibitors; Disease Models, Animal; Immunohistochemistry; Immunotoxins; Male; N-Glycosyl Hydrolases; Neural Inhibition; Neural Pathways; Neurons; Phenylcarbamates; Psychotic Disorders; Rats; Rats, Sprague-Dawley; Reflex, Startle; Ribosome Inactivating Proteins, Type 1; Rivastigmine; Saporins; Treatment Outcome | 2002 |
[Clozapine for the treatment of psychosis in 3 elderly patients with Parkinson's disease].
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Male; Neuroprotective Agents; Olanzapine; Parkinson Disease; Phenylcarbamates; Psychotic Disorders; Rivastigmine; Treatment Outcome | 2004 |